Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.76 |
| ▸ | LIFR | P42702 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28512839 | 0.87 | NR1H4 (1.00) | NR1H4LIFRPPARD | |
| SCHEMBL2152799 | 0.85 | NR1H4 (0.75) | NR1H4LIFR | |
| SCHEMBL2152906 | 0.84 | NR1H4 (0.76) | NR1H4LIFRPPARD | |
| SCHEMBL28530650 | 0.83 | NR1H4 (1.00) | NR1H4LIFRPPARD | |
| SCHEMBL28518144 | 0.80 | NR1H4 (1.00) | NR1H4LIFRPPARD | |
| SCHEMBL4836990 | 0.80 | NR1H4 (0.72) | NR1H4LIFRPPARD | |
| SCHEMBL28530295 | 0.78 | NR1H4 (1.00) | NR1H4LIFRPPARD | |
| SCHEMBL19499079 | 0.78 | NR1H4 (0.82) | NR1H4LIFRPPARD | |
| SCHEMBL20094448 | 0.77 | NR1H4 (0.73) | NR1H4LIFRPPARD | |
| SCHEMBL4835608 | 0.77 | NR1H4 (0.69) | NR1H4LIFRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085662-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING PERSISTENCE AND EXPRESSION OF EPISOMAL VIRUSES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-25 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| US-8193192-B2 | Heterocyclic FXR binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2012-06-05 | — | — | US | disclosed |
| US-8193192-B2 | Heterocyclic FXR binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20100210660-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210660-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210660-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1I3, NR1I2 | NR1H4 1/4885LIFR 1534/4885PPARD 46/4885 |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885LIFR 3138/4885PPARD 136/4885 |
| US-20210085662-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING PERSISTENCE AND EXPRESSION OF EPISOMAL VIRUSES | NR1H4, ABCB11, FXR1 | NR1H4 1/4885LIFR 2784/4885PPARD 550/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | NR1H4 1/4885LIFR 2940/4885PPARD 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.